Effectors of HIV-1 protease peptidolytic activity

被引:14
作者
Porter, DJT [1 ]
Hanlon, MH [1 ]
Carter, LH [1 ]
Danger, DP [1 ]
Furfine, ES [1 ]
机构
[1] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1021/bi010418p
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High concentrations of salts dramatically affect the interaction of small ligands with HIV-1 protease. For instance, the K-m and k(cat) values for Abz -Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2 (S) increased 120-fold and 3-fold, respectively, as the NaCl concentration in the assay decreased from 4.0 to 0.5 M. The Kd value for the competitive inhibitor amprenavir increased 12-fold over this concentration range of NaCl. The bimolecular rate constant for association of enzyme with amprenavir was independent of NaCl concentration, whereas the dissociation rate constant decreased with increasing NaCl concentration. Polyanionic polymers such as heparin or poly A substituted for NaCl. For example, the value of k(cat)/K-m for S was 0.18 muM(-1) s(-1) when the enzyme (< 10 nM) was assayed in the standard buffer supplemented with 5 mM NaCl. If 0.01% poly A were included, the value of k(cat)/K-m increased to 8.6 muM(-1) s(-1). A DNA oligomer (23-mer) with an hexachlorofluoresceinyl moiety linked to the 5 ' end was studied as a model polyanionic polymer. The enzyme bound HF23 (K-d < 1 nM) with concomitant quenching of the hexachlorofluoresceinyl fluorescence. The stoichiometry for binding was 3 mol of enzyme per mol of oligomer. The hydrolytic activity of the enzyme with this oligomer was similar to that observed with poly A or high salt concentration when the molar ratio of oligomer to enzyme was greater than one. The results presented herein demonstrate that polyanionic polymers substitute for salts as effectors of HIV protease.
引用
收藏
页码:11131 / 11139
页数:9
相关论文
共 25 条
[1]   INHIBITION OF HIV PROTEASE ACTIVITY BY HETERODIMER FORMATION [J].
BABE, LM ;
PICHUANTES, S ;
CRAIK, CS .
BIOCHEMISTRY, 1991, 30 (01) :106-111
[2]  
Bevington P.R., 1969, DATA REDUCTION ERROR
[3]  
CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9960
[4]   2-STEP BINDING MECHANISM FOR HIV PROTEASE INHIBITORS [J].
FURFINE, ES ;
DSOUZA, E ;
INGOLD, KJ ;
LEBAN, JJ ;
SPECTOR, T ;
PORTER, DJT .
BIOCHEMISTRY, 1992, 31 (34) :7886-7891
[5]  
FURFINE ES, 2000, HANDB EXP PHARM, V140, P49
[6]   USE OF PROTEIN UNFOLDING STUDIES TO DETERMINE THE CONFORMATIONAL AND DIMERIC STABILITIES OF HIV-1 AND SIV PROTEASES [J].
GRANT, SK ;
DECKMAN, IC ;
CULP, JS ;
MINNICH, MD ;
BROOKS, IS ;
HENSLEY, P ;
DEBOUCK, C ;
MEEK, TD .
BIOCHEMISTRY, 1992, 31 (39) :9491-9501
[7]   HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE .2. USE OF PH RATE STUDIES AND SOLVENT KINETIC ISOTOPE EFFECTS TO ELUCIDATE DETAILS OF CHEMICAL MECHANISM [J].
HYLAND, LJ ;
TOMASZEK, TA ;
MEEK, TD .
BIOCHEMISTRY, 1991, 30 (34) :8454-8463
[8]   HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE .1. INITIAL VELOCITY STUDIES AND KINETIC CHARACTERIZATION OF REACTION INTERMEDIATES BY O-18 ISOTOPE EXCHANGE [J].
HYLAND, LJ ;
TOMASZEK, TA ;
ROBERTS, GD ;
CARR, SA ;
MAGAARD, VW ;
BRYAN, HL ;
FAKHOURY, SA ;
MOORE, ML ;
MINNICH, MD ;
CULP, JS ;
DESJARLAIS, RL ;
MEEK, TD .
BIOCHEMISTRY, 1991, 30 (34) :8441-8453
[9]  
JORDAN SP, 1992, J BIOL CHEM, V267, P20028
[10]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690